Children's cancer group recommends global evaluation system for neuroblastoma to improve treatment

December 09, 2008

An international coalition of pediatric cancer physicians and researchers has developed new systems to standardize studies of neuroblastomas across the world. In the December issue of the Journal of Clinical Oncology, the International Neuroblastoma Risk Group (INRG) presents three sets of papers outlining a: standard classification system; pre-treatment staging system; and an analysis of a rare group of patients.

The INRG studies provide for a unified system of clinical trials that will enable quicker identification of optimal treatments for neuroblastoma.

Neuroblastoma is the most common solid cancer that occurs outside the cranium during childhood. For some young children, it disappears with minimal treatment. In other children, it can be relentlessly aggressive, with a high likelihood of death. Predicting the behavior of this tumor is crucial in planning appropriate treatment.

The INRG task force is co-chaired by Susan Cohn, professor and director of clinical sciences at the University of Chicago Comer Children's Hospital, and Andrew Pearson, chairman of paediatric oncology at the Institute of Cancer Research at Royal Marsden Hospital in the UK.

Cohn says that in the past, criteria used to predict tumor behavior and stratify treatment have not been uniform throughout the world, which makes it impossible to directly compare clinical trial results. The INRG classification system is designed to create consistency of risk group assignment around the globe, and will facilitate clinical research.

"We strongly recommend that cooperative groups begin using this classification system now," Cohn says.

"The system will allow the direct comparison of results from clinical trials conducted in different regions of the world and will help us determine the best treatment strategies for patients with neuroblastoma," she adds. "By working together, physicians will be able to ask questions about treatment approaches that would otherwise not be possible to ask in a single cooperative group or country because of the small numbers of patients. We plan to continue to expand this database, and as new molecular tools are developed to test cancer genetics, the INRG Classification System will be refined."

University of Chicago Medical Center

---

---

	Neuroblastoma by Nai-Kong V. Cheung (Editor), Susan L. Cohn (Editor) Neuroblastoma is a medical enigma. As a childhood neoplasm arising from neural crest cells, it is characterized by diverse clinical behaviors ranging from spontaneous remission to rapid tumor progression and death. Although clinical outcome can be predicted to a large extent by the stage of disease and the age at diagnosis, an in-depth understanding of its clinico-pathological behavior, now greatly aided by sophisticated molecular genetic profiling, will improve diagnostic precision and refine risk-based therapies. Comprehensive international efforts have advanced our understanding of tumor biology and improved the clinical management of children with neuroblastoma. This book reviews our current understanding of the genes and biological pathways that contribute to neuroblastoma...
	Neuroblastoma (Pediatric Cancer: Diagnosis, Therapy, and Prognosis, Vol. 1) by M.A. Hayat (Editor) Introduction of new technologies and their applications to neuroblastoma diagnosis, treatment, and therapy assessment are explained. Role of molecular ghenetics in diagnosis and therapy for neuroblastoma patients is detailed. Molecular detection of minimal residual neuroblastoma is described. Magnetic resonance imaging and  spectroscopy are detailed for diagnosing this solid, extracranial cancer. Targets for therapeutic intervention in neuroblastoma are identified, including targeting multidrug resistance in this cancer. Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention. The effectiveness of chemotherapy with oral irinotecan and temozolomide is explained. The role of transcription factors (GATA) in neuroblastoma pregression is  also included.
	Olfactory neuroblastoma.(PATHOLOGY CLINIC)(Disease/Disorder overview): An article from: Ear, Nose and Throat Journal by Lester D.R. Thompson (Author) This digital document is an article from Ear, Nose and Throat Journal, published by Thomson Gale on September 1, 2006. The length of the article is 798 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Olfactory neuroblastoma.(PATHOLOGY CLINIC)(Disease/Disorder overview) Author: Lester D.R. Thompson Publication: Ear, Nose and Throat Journal (Magazine/Journal) Date: September 1, 2006 Publisher: Thomson Gale Volume: 85 Issue: 9 Page: 569(2) Article Type: Disease/Disorder overview Distributed by Thomson...
	Advances Neuroblastoma Res (Progress in cancer research and therapy) by Evans (Author)
	The Official Parent's Sourcebook on Neuroblastoma: A Revised and Updated Directory for the Internet Age by Icon Health Publications (Author) This sourcebook has been created for parents who have decided to make education and Internet-based research an integral part of the treatment process. Although it gives information useful to doctors, caregivers and other health professionals, it also tells parents where and how to look for information covering virtually all topics related to neuroblastoma, from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from various agencies are reproduced to give you some of the latest official information available to date on neuroblastoma. Following an introductory chapter, the sourcebook is organized into three...
	The Neurology of Neuroblastoma: Neuroblastoma as a Neurobiological Disease by Nina Felice Schor (Author) Neuroblastoma is the single most common solid tumor of childhood. Although children with small primary neuroblastomas alone are almost always cured by surgery, 65% of children with neuroblastoma already have large bulky tumors or metastatic disease by the time of initial diagnosis. For these children, the 5-year survival rate is only somewhere between 5% and 20% with therapies including surgery, radiation, chemotherapy, and bone marrow transplantation. Dr Schor outlines a new approach to these tumors in order to make a difference for these children. There is much information to support the notion that neuroblastomas represent a developmental aberration of the nervous system, rather than a de novo abnormality in a previously normal cell. While the remote, paraneoplastic effects of...
	Advances in neuroblastoma research: Proceedings of the Third Symposium on Advances in Neuroblastoma Research held in the Children's Hospital of ... in clinical and biological research) by Liss (Publisher)
	The Epidemiology of Neuroblastoma by Stefano Parodi (Author), Riccardo Haupt (Author) Neuroblastoma is a cancer of the sympathetic nervous system. It is the most common tumor in the first year of life and the most common solid extra-cranial cancer in childhood. Neuroblastoma represents an enigmatic disease, in that some cases, especially in infants, tend to spontaneously regress, even in advanced states, while many patients are refractary to any therapeutical approach and show an inexorable clinical course. As most of the other solid cancers in children, the distribution of Neuroblastoma risk worldwide is only partly known. In Western countries, its incidence varies between 7 and 16 cases per million children and it tends to decrease increasing the age.Besides, survival of patients affected by such disease, in relation with clinical and biological characteristics, have...
	Cancer in the First Year of Life: Leukemias, Neuroblastomas, Soft Tissue Sarcomas (Contributions to Oncology) by Germany) Italo-German Workshop on Pediatric Oncology 1989 (Braunfels (Author), L. Cordero Di Montezemolo (Author), A. Pession (Author), Fritz Lampert (Author), Fritz Lampert (Contributor)
	Neuroblastomas: Webster's Timeline History, 1949 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Neuroblastomas," including when used in literature (e.g. all authors that might have Neuroblastomas in their name). As such, this book represents the largest compilation of timeline events associated with Neuroblastomas when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts,...